TISIDB

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Single-pass type I membrane protein.
Domain	PF13882 Bravo-like intracellular region PF00041 Fibronectin type III domain PF07679 Immunoglobulin I-set domain PF00047 Immunoglobulin domain
Function	Cell adhesion, ankyrin-binding protein which may be involved in neurite extension, axonal guidance, synaptogenesis, myelination and neuron-glial cell interactions.

> Gene Ontology [ TOP ]
Biological Process	GO:0002175 protein localization to paranode region of axon GO:0006612 protein targeting to membrane GO:0007009 plasma membrane organization GO:0007043 cell-cell junction assembly GO:0007272 ensheathment of neurons GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007422 peripheral nervous system development GO:0008366 axon ensheathment GO:0010927 cellular component assembly involved in morphogenesis GO:0019226 transmission of nerve impulse GO:0021700 developmental maturation GO:0030913 paranodal junction assembly GO:0032288 myelin assembly GO:0034113 heterotypic cell-cell adhesion GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0035637 multicellular organismal signaling GO:0042551 neuron maturation GO:0042552 myelination GO:0045161 neuronal ion channel clustering GO:0045162 clustering of voltage-gated sodium channels GO:0045216 cell-cell junction organization GO:0048469 cell maturation GO:0048667 cell morphogenesis involved in neuron differentiation GO:0050808 synapse organization GO:0061564 axon development GO:0071205 protein localization to juxtaparanode region of axon GO:0072657 protein localization to membrane GO:0072659 protein localization to plasma membrane GO:0072661 protein targeting to plasma membrane GO:0090002 establishment of protein localization to plasma membrane GO:0090150 establishment of protein localization to membrane GO:0097485 neuron projection guidance GO:0099612 protein localization to axon GO:1990778 protein localization to cell periphery
Molecular Function	GO:0086080 protein binding involved in heterotypic cell-cell adhesion GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion
Cellular Component	GO:0005902 microvillus GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction GO:0030424 axon GO:0033010 paranodal junction GO:0033267 axon part GO:0033268 node of Ranvier GO:0033270 paranode region of axon GO:0043194 axon initial segment GO:0043209 myelin sheath GO:0044304 main axon GO:0097386 glial cell projection GO:0097454 Schwann cell microvillus GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs)
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-445095: Interaction between L1 and Ankyrins R-HSA-373760: L1CAM interactions R-HSA-447043: Neurofascin interactions R-HSA-6798695: Neutrophil degranulation

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NFASC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NFASC in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NFASC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.257	0.673
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.031	0.977
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.466	0.6
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.348	0.387
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.174	0.938
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.559	0.831
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.446	0.00923
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.641	0.115
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.361	0.192
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.414	0.674
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.266	0.313
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.141	0.392

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NFASC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	33.3	-23.3	0.423
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	4.1	7	0.339
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	5.1	6	0.373
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	23.5	-4.5	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	36.4	-21	0.357
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	12.5	-12.5	0.52
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	7.4	0.5	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NFASC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NFASC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NFASC. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NFASC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NFASC expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NFASC and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NFASC
Name	neurofascin
Aliases	NRCAML; KIAA0756; FLJ46866; NF; neurofascin homolog (chicken); neurofascin homolog
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NFASC collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NFASC